Recent news of a meningitis B (MenB) outbreak in Kent in March 2026 has understandably raised concern, particularly among parents and young adults. The outbreak, centred around Canterbury, led to over 20 confirmed cases and several deaths, with cases emerging rapidly over a short period.
While such outbreaks are rare, they highlight the importance of early recognition and prevention, including vaccination. It is worth noting that the risk of contracting meningitis B is very low in those over 25 and under 16—but it is not zero.
What is meningitis B?
MenB is a form of bacterial meningitis caused by Neisseria meningitidis. It can lead to:
- Meningitis (infection of the lining of the brain)
- Septicaemia (blood poisoning)
These conditions can develop quickly and may become life-threatening within hours. The bacteria spread through close, prolonged contact, such as living together or sharing drinks.
Symptoms to be aware of
Early symptoms can resemble a viral illness but may progress rapidly:
- Fever, headache, vomiting
- Neck stiffness and sensitivity to light
- Cold hands and feet, limb pain
- Confusion or drowsiness
- A rash that does not fade under pressure
Urgent medical assessment is essential if meningitis is suspected.
Vaccination: what is available?
The MenB vaccine (Bexsero®) has been part of the UK childhood immunisation schedule since 2015, given at:
- 8 weeks
- 16 weeks
- 1 year (booster)
As this programme was not introduced retrospectively, many older children, teenagers and adults remain unvaccinated. This “immunity gap” has been highlighted by the recent outbreak, particularly among students and young adults.
Private vaccination options: Bexsero® and Trumenba®
Private MenB vaccination is available. Two vaccines can be used: Bexsero® and Trumenba®.
While both provide protection against MenB, they differ in formulation, licensing and dosing schedules. They are not interchangeable, as they contain different antigen components, and the same vaccine must be used to complete a full course.
At Palace Gate Practice, we most commonly provide Trumenba®:
- Authorised in the European Union in 2017 for individuals aged 10 years and older
- Not part of the NHS routine programme but available privately
- Standard schedule: 2 doses at 0 and 6 months
- A booster may be considered for those at ongoing risk
Who should consider private MenB vaccination?
Private vaccination may be appropriate for:
- Older children, teenagers and students who were not vaccinated as infants
- Individuals in shared living environments
- Those with underlying medical risk factors
- Patients seeking additional reassurance, particularly in light of recent outbreaks
- People with increased exposure to close-contact settings
Meningitis B remains a rare but serious illness, and outbreaks—while uncommon—can develop quickly. Awareness of symptoms and prompt medical care are essential.
Vaccination remains the most effective way to reduce risk. In a private GP setting, we are able to offer personalised advice and access to MenB vaccination where appropriate.
If you would like to discuss your risk or arrange vaccination, our GP team would be very happy to help: contact our team today.